<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03494387</url>
  </required_header>
  <id_info>
    <org_study_id>VIXIE2018</org_study_id>
    <nct_id>NCT03494387</nct_id>
  </id_info>
  <brief_title>VitamIn and oXygen Interventions and Cardiovascular Events</brief_title>
  <acronym>VIXIE</acronym>
  <official_title>Hyperoxia and Antioxidants During Major Non-cardiac Surgery and Risk of Cardiovascular Complications, a Blinded 2x2 Factorial Randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Bispebjerg and Frederiksberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Bispebjerg and Frederiksberg</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines the risks and benefits of antioxidants and normal versus high inspiratory&#xD;
      oxygen fraction during anaesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with risk factors for developing postoperative cardiac complications will be&#xD;
      enrolled in the study. The patients will be randomised to receiving antioxidants or placebo&#xD;
      perioperatively and 30% or 80% inspiratory oxygen concentration during anaesthesia and 2&#xD;
      hours postoperatively. The primary outcome is MINS (myocardial injury after non-cardiac&#xD;
      surgery). The antioxidants are ascorbic acid (vitamin C) 3 grams intravenously preoperatively&#xD;
      and N-acetylcysteine 100 milligrams/kilogram body weight intravenous infusion for 4 hours,&#xD;
      starting at the same time as anaesthesia.&#xD;
&#xD;
      The study is a long-term follow-up study of the risk of mortality, MI and readmissions&#xD;
      performed at 1 year after inclusion of the last patient. Two other follow-up studies are&#xD;
      planned: One investigation of ischaemic troponin elevations defined as peak troponin levels&#xD;
      above the internationally defined thresholds without extracardiac causes; another&#xD;
      investigating the intervention effects in the subgroup of patients undergoing vascular&#xD;
      surgery with specific emphasis on episodes of intraoperative hypotension within the following&#xD;
      thresholds: MAP below 70 mmHg, 65 mmHg, 60 mmHg and 55 mmHg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2018</start_date>
  <completion_date type="Actual">March 24, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial injury after non-cardiac surgery (MINS)</measure>
    <time_frame>30 days</time_frame>
    <description>Troponin measurement the first 3 postoperative days. Assessed by area under the curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>During the study period until completion of last visit of last patient</time_frame>
    <description>Assessed as time to event analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal myocardial infarction</measure>
    <time_frame>During the study period until completion of last visit of last patient</time_frame>
    <description>Assessed as time to event analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-fatal Serious Adverse Event</measure>
    <time_frame>During the study period until completion of last visit of last patient</time_frame>
    <description>Assessed as time to event analysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Surgical site infection</measure>
    <time_frame>Assessed at postoperative day 30</time_frame>
    <description>Infection in surgical area as defined by the Center for Disease Control</description>
  </other_outcome>
  <other_outcome>
    <measure>Pneumonia</measure>
    <time_frame>Assessed at postoperative day 30</time_frame>
    <description>Pneumonia as defined by the Center for Disease Control</description>
  </other_outcome>
  <other_outcome>
    <measure>Sepsis</measure>
    <time_frame>Assessed at postoperative day 30</time_frame>
    <description>Sepsis as defined by the joint task force by the European Society of Intensive Care Medicine and the Society of Critical Care Medicine</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute respiratory failure</measure>
    <time_frame>Assessed at postoperative day 30</time_frame>
    <description>Acute respiratory failure defined as the need for controlled ventilation or oxygen saturation of 900% or less despite of oxygen therapy</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>Assessed at postoperative day 30</time_frame>
    <description>Acute kidney injury as defined Kidney Disease Improving Global Outcomes guidelines</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Postoperative Cardiac Complication</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>80% versus 30% inspiratory oxygen concentration</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antioxidants</intervention_name>
    <description>Antioxidants versus placebo</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Ascorbic acid</other_name>
    <other_name>N-acetylcysteine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        All of the listed criteria (1.-4.) must be met.&#xD;
&#xD;
          1. Age 45 years or above&#xD;
&#xD;
          2. Elective or acute surgery in general anaesthesia&#xD;
&#xD;
          3. Scheduled for abdominal, orthopaedic, or vascular surgery with expected surgery&#xD;
             duration of one hour or more.&#xD;
&#xD;
          4. Fulfil any 1 of the following 5 criteria:&#xD;
&#xD;
               1. - History of coronary artery disease including angina&#xD;
&#xD;
               2. - History of stroke&#xD;
&#xD;
               3. - Undergoing vascular surgery&#xD;
&#xD;
               4. - History of peripheral arterial disease&#xD;
&#xD;
               5. - Any 2 of the following 8 criteria: i. Acute surgery ii. Current or previous&#xD;
                  daily smoking iii. History of hypertension iv. Diabetes mellitus requiring&#xD;
                  medical treatment v. History of transient cerebral ischemia vi. Plasma creatinine&#xD;
                  &gt;175 ÂµM vii. Age 70 years or above viii. History of congestive heart failure&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Surgery within 30 days prior to operation&#xD;
&#xD;
          2. Arterial oxygen saturation below 90% without oxygen supplementation&#xD;
&#xD;
          3. Inability to give informed consent&#xD;
&#xD;
          4. Drug allergy towards any of the drugs involved in the trial&#xD;
&#xD;
          5. Previous treatment with bleomycin&#xD;
&#xD;
          6. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Abdominalcentret, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HovedOrtoCentret, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg and Frederiksberg Hospital, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2018</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Bispebjerg and Frederiksberg</investigator_affiliation>
    <investigator_full_name>Cecilie Petersen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Antioxidant</keyword>
  <keyword>Hyperoxia</keyword>
  <keyword>Troponin</keyword>
  <keyword>MINS</keyword>
  <keyword>Ascorbic acid</keyword>
  <keyword>N-acetylcysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

